Radiation oncology firm Elekta has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Clarity 4D monitoring software, which monitors motion in the prostate and surrounding tissues and organs during radiation therapy for prostate cancer.
The software continuously visualizes the prostate's location in real-time and with submillimeter accuracy during the delivery of radiation, according to the company. It is designed to enable hypofractionation techniques that shorten the treatment schedule.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
